ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead boosts antiviral drug investment

by Ryan Cross
July 25, 2019 | APPEARED IN VOLUME 97, ISSUE 30

 

Gilead Sciences has licensed three small-molecule antiviral programs from Novartis. Gilead will pay an undisclosed sum and up to $291 million in future milestones for Novartis’s herpes virus, influenza, and rhinovirus programs. Separately, Gilead will pay Durect $25 million to license a long-lasting injectable antiviral for HIV. Durect could earn $145 million more in milestone payments, and Gilead has the option to license additional Durect antiviral programs for HIV and hepatitis B.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment